Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

Sir,

I compared Table 1 of your publication on the GAL-INT-1 trial with the
similar table of the publication of Raskind et al (Neurology 2000, 54:
2264), describing the galantamin US study of almost identical design.

I was wondering whether the mistake regarding the percentage of
smokers should have read "White Race" - this would make figures of 90%
very feasible. Indeed, I would think that 90% of non-smokers (as you
suggest in your correction) would also be a fairly high figure.

Yours sincerely,

Frank Berger